The role of the vesicular monoamine transporter 2 in the inhibitory effect of tetrabenazine and valbenazine compared to reserpine on the vesicular release of monoamine transmitters
The difference observed between the two types of VMAT-2 inhibitors might give some explanation of why, in response to TBZ or VBZ treatment, the occurrence of depression or Parkinsonism as side effects is seen very rarely or not at all, and in the case of RSP, it is relatively frequent.
Authors
- Beáta Sperlágh (ORCID: https://orcid.org/0000-0003-0099-591X)
- E. Sylvester Vizi (ORCID: https://orcid.org/0000-0002-9557-4597)
- Erika-Gyöngyi Bán (ORCID: https://orcid.org/0000-0001-7520-1454)
- Fruzsina Maácz
- Attila Brassai
Institutions
- Semmelweis University (HU)
- Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș (RO)
- HUN-REN Institute of Experimental Medicine (HU)
Publication Details
- Journal
- Frontiers in Cellular Neuroscience
- Published
- 2025-11-07
- DOI
- https://doi.org/10.3389/fncel.2025.1648613
- Primary Topic
- Neurotransmitter Receptor Influence on Behavior
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission